Results 111 to 120 of about 1,321,964 (375)

Development and Validation of Machine Learning‐Based Marker for Early Detection and Prognosis Stratification of Nonalcoholic Fatty Liver Disease

Advanced Science, EarlyView.
This study constructs a stacked multimodal machine learning model for nonalcoholic fattly liver disease (NAFLD) by integrating genetic and clinical features, and synthesize an in‐silico quantitative marker (ISNLD) that enables personalized risk stratification for intrahepatic and extrahepatic outcomes of high‐risk individuals of NAFLD.
Lushan Xiao, Lin Zeng, Jiaren Wang, Chang Hong, Ziyong Zhang, Chengkai Wu, Hao Cui, Yan Li, Ruining Li, Shengxing Liang, Qijie Deng, Wenyuan Li, Xuejing Zou, Pengcheng Ma, Li Liu   +14 more
wiley   +1 more source

Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment

Journal of the Formosan Medical Association, 2021
Background/Purpose: Effective antiviral-therapy can reduce the risk of liver cirrhosis related hepatocellular carcinoma in patients with chronic hepatitis B and hepatitis C. Yet, the difference of hepatocellular carcinoma development in chronic hepatitis
Ming-Tsung Lin, Kuo-Chin Chang, Yi-Hao Yen, Ming-Chao Tsai, Chien-Hung Chen, Jing-Houng Wang, Chang-Chun Hsiao, Yueh-Hsia Chiu, Tsung-Hui Hu   +8 more
doaj  

The Iowa Viral Hepatitis Strategic Plan 2012-2016, August 26, 2014 [PDF]

, 2014
Since the creation of the first viral hepatitis plan in 2004 several documents and advancements have been released that help Iowa plan and prioritize this revision of our hepatitis plan.

core  

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas, Hoffmann, Robert M., Hopf, Uwe, Lafrenz, Michael, Leifeld, Ludger, Pape, Gerd R., Spengler, Ulrich, Teuber, Gerlinde, Zeuzem, Stefan   +8 more
core   +1 more source

Chronic hepatitis C and liver fibrosis.

World Journal of Gastroenterology, 2014
Chronic infection with hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide and predisposes to liver fibrosis and end-stage liver complications. Liver fibrosis is the excessive accumulation of extracellular matrix
G. Sebastiani, K. Gkouvatsos, K. Pantopoulos   +2 more
semanticscholar   +1 more source

Targeted Delivery of α‐ketoglutarate to Macrophages in Bone: A Novel Therapeutic Strategy for Improving Fracture Healing in Type 2 Diabetes

Advanced Science, EarlyView.
The study reveals that glutaminolysis in macrophages is inhibited under type 2 diabetes mellitus (T2DM) conditions, which impedes fracture healing by reducing bone morphogenetic protein 2 (BMP2) production through increased cytosine methylation on the promoter.
Jing Wang, Jiahao Cao, Siqi Zhang, Hongli Chen, Xuebing Yu, Xinli Wang, Tianji Wang, Wei Cao, Wengang Dong, Xinsen Lin, Jia Li, Wei Lei, Yafei Feng   +12 more
wiley   +1 more source

Arthritis in Chronic Hepatitis C Infection: Is It Rheumatoid Like Arthritis or True Rheumatoid Arthritis?

Jurnal Penyakit Dalam Indonesia, 2020
Hepatitis C infection is often found in asymptomatic patients accidentaly during general check up, where there is increment levels of transaminases. Symptoms of hepatitis C infection include weakness, sleep disorders, nausea and so on.
Jefri Pratama Susanto, Syifa Mustika, Bogi Pratomo   +2 more
doaj   +1 more source

Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C [PDF]

, 2015
Hepatitis C virus (HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma (HCC), one of the most common fatal cancers worldwide - fourth for ...
Fassina, Giorgio, Gallotta, Andrea, MARTINI, ANDREA, PONTISSO, PATRIZIA   +3 more
core   +1 more source

Gelsolin's Protective Role in MASH through F‐Actin Regulation and P53 Degradation

Advanced Science, EarlyView.
Gelsolin (GSN) maintains liver metabolic homeostasis by promoting MDM2‐mediated P53 degradation and inhibiting F‐actin/Yes‐associated protein (YAP) overactivation. Loss of GSN impairs P53 degradation, increases lipid deposition, and enhances YAP‐driven fibrosis and inflammation in metabolic‐associated steatohepatitis.
Yiwei Lu, Tong Ji, Zhichao Ye, Jianing Yan, Chao Wang, Jiachen Chen, Ziyang Jin, Yongji Zhu, Xiujun Cai, Yifan Wang   +9 more
wiley   +1 more source

Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. [PDF]

, 2013
Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
Agnello, Aizaki, Amako, Amako, Anderson, Atsukawa, Bader, Bishop, Boulant, Bradley, Bradley, Brasaemle, Bulankina, Calland, Catherine Schuster, Chhatwal, Chojkier, Ciesek, Clark, Dallinga-Thie, Daniel Felmlee, Dao Thi, Dienes, Enjoji, Esau, Forde, Fraser, Goldwasser, Grove, Haid, Harrison, Herker, Hijikata, Hirata, Hsu, Huang, Icard, Ishibashi, Jopling, Kaito, Kanto, Koutsoudakis, Lambert, Lanford, Lin, Lindenbach, Mancone, Martin, Marzouk, Mathieu Lefevre, McHutchison, Meex, Meunier, Miyanari, Mohamed Hafirassou, Nahmias, Nakamuta, Nishimura, Packard, Pecheur, Petit, Poynard, Prentoe, Pumeechockchai, Ramcharran, Reiss, Rocha-Perugini, Roe, Romero-Brey, Sakamoto, Sarasin-Filipowicz, Scholtes, Schuster, Serfaty, Sezaki, Shavinskaya, Shi, Shimakami, Stanford, Targett-Adams, Thomas Baumert, Thomssen, Tsai, Voisset, Wakita, Weng, Westin, Ye, Zeisel   +88 more
core   +6 more sources